FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience

American Journal of Hematology

Volumn 84, Issue 10, 2009, Pages 690-692

  Candoni, Anna ^a   Simeone, Erica ^a   Tiribelli, Mario ^a   Malagola, Michele ^b   Russo, Domenico ^b   Fanin, Renato ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CARDIOTOXICITY; DEATH; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG RESPONSE; ENTERITIS; ERYTHROCYTE CONCENTRATE; FEMALE; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIRUS REACTIVATION; WORLD HEALTH ORGANIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION; VIDARABINE; YOUNG ADULT;

EID: 70349482533     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21516     Document Type: Article

References (30)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907.
2. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990;75:27-32.
3. Stone RM, O'donnell MR, Sekers MA. Acute myeloid leukemia. Haematology 2004;1:98-117.
4. Deschler B, Lubbert M. Acute myeloid leukemia: Epidemiology and etiology. Cancer 2006;107:2099-2107. (Pubitemid 44665642)
5. Wood P, Burgess R, Macgregor A, et al. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994;87:509-514. (Pubitemid 24230015)
6. Damiani D, Tiribelli M, Raspadori D, et al. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematol Oncol 2007;25:38-43. (Pubitemid 46474313)
7. Mròzek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Haematology Am Soc Educ Program. 2006;169-177.
8. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non lymphocytic leukemias: Biological and clinical implications. Br J Haematol 1999;104:328-335. (Pubitemid 29083342)
9. Clavio M, Gatto S, Beltrami G, et al. Fludarabine, cytarabine, idarubicin and G-CSF (FLAG-Ida), high dose cytarabine and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients. J Exp Clin Cancer Res 2002;21:481-487. (Pubitemid 36193797)
10. Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol 1997;99:949-1944 (Pubitemid 28047164)
11. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93:2478-2484. (Pubitemid 29181178)
12. Jackson G. Use of fludarabine in the treatment of acute myeloid leukemia. Hematology J 2004;5:62-67. (Pubitemid 38744821)
13. Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukemia or myelodysplastic syndromes. Br J Haematol 2004;124:26-32. (Pubitemid 38021620)
14. Ferrara F, D'arco AM, De Simone M, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica 2005;90:776-784.
15. Russo D, Pricolo G, Michieli M, et al. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymph 2001;40:335-343. (Pubitemid 32401389)
16. Russo D, Malagola M, De Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients. Br J Haematol 2005;131:172-179. (Pubitemid 43899682)
17. Malagola M, Damiani D, Martinelli G, et al. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. Br J Haematol 2007;136:87-95. (Pubitemid 44912592)
18. Farag SS, Ruppert AS, Mrózek K, et al. Outcome of induction and post remission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study. J Clin Oncol 2005;23:482-493. (Pubitemid 46224225)
19. Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus Idarubicin or Daunorubicin as induction and consolidation therapy for previously untreated adult patient with acute myeloid leukemia. Blood 1992;79:313-319.
20. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of poor risk acute myeloid leukemias. Leukemia 1994;8:1842-1846.
21. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996;81:513-520. (Pubitemid 126506555)
22. Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: Results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007;138:186-195. (Pubitemid 46976329)
23. Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998;58:105-109. (Pubitemid 28268085)
24. De La Rubia J, Regadera A, Martin G, et al. FLAG-IDA regimen (fludarabine cytarabine, idarubicin and G-CSF) in the treatment of patients with high risk myeloid malignancies. Leuk Res 2002;26:725-730. (Pubitemid 34628370)
25. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-124. (Pubitemid 23059984)
26. Tosi P, Visani G, Ottaviani E, et al. Fludarabine+Ara-C+G-CSF: Cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994;8:2076-2082.
27. Michelutti A, Michieli M, Damiani D, et al. Effect of fludarabine and arabinosyl cytosine on multidrug resistant cells. Haematologica 1997;82:143-147. (Pubitemid 28023330)
28. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311-2318.
29. Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: Remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996;14:1345-1352 (Pubitemid 126424612)
30. Cheson DB, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international Working Group for Diagnosis, Standardization of response Criteria, Treatment Outcomes, and reporting Standards for therapeutic Trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.